Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
The optimal regimen of brentuximab vedotin for CD30+ cutaneous lymphoma: are we there yet? The British journal of dermatology Geller, S., Myskowski, P. L., Kim, Y. H., Moskowitz, A., Horwitz, S. 2018; 178 (2): 571
View details for PubMedID 29023638